Respiratory Disease Panel

PCL’s Respiratory Disease Panel is focused on serving:

  • Skilled Nursing Facilities
  • ENT Physicians
  • Geriatric, Primary Care & Family Physicians
  • Pediaticians

Respiratory Disease Panel Benefits

  • Testing for both infections and viruses has a large impact of the types of treatments that will be effective.
  • Quickly identifies all organisms and pathogens in the respiratory tract and potential bacterial antibiotic resistance allowing providers to offer more effective, supportive care.

Respiratory Disease Statistics

  • Every year, influenza leads to respiratory tract infections in 5-15% of the population and severe illness in 3-5 million people.
  • As of June 2021, the United States has seen over 33 million COVID-19 cases and nearly 600 thousand associated deaths.

The Respiratory Panel detects the following:

  • BACTERIAL
    • Bordetella (Pan)
    • Bordetella pertusus
    • Chlamydophila pneumoniae
    • Haemophiilus influenzae
    • Klebsiella pneumoniae complex
    • Legionella pneumophila
    • Mycoplasma pneumoniae
    • Staphylococcus aureus
    • Streptocccus pneumoniae
  • VIRAL
    • Adenovirus
    • Coronavirus 229E
    • Coronavirus HKU1
    • CoronavirusNL63
    • Coronavirus OC43
    • Enterovirus (pan assay)
    • Enterovirus D68
    • Herpevirus (HHV6)
    • HHV4 (Epstein-Barr virus)
    • HHV5 (cytomegalovirus)
    • Metapneumovirus (hMPV)
    • Influenza A (pan)
    • Influenza A/H1-2009
    • Influenza A/H3
    • Influenza B
    • Parainfluenza virus 1
    • Parainfluenza virus 2
    • Parainfluenza virus 3
    • Parainfluenza virus 4
    • Respiratory Syncytial Virus (RSV A)
    • Respiratory Syncytial Virus (RSV B)
    • Rhinovirus
    • SARS-CoV-2

Results will become available online within 24 to 48 hours of specimen receipt followed by hard copy in the mail and fax if requested.